Clearmind Medicine (CMND) announced that it is evaluating CMND-100, for eligibility for the FDA’s breakthrough therapy designation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
- Trump Trade: President to sign order on psychedelic used for PTSD
- Trump to sign order on psychedelic used for PTSD, CBS News says
- Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
- Clearmind announces DSMB recommendation to continue CMND-100 trial